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global cardiovascular disease burden (1). Although BP is
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Table 1
Baseline Characteristics of Individuals in the
Derivation and Validation Cohorts
Derivation Cohort
(n ¼ 1,272)
Validation Cohort
(n ¼ 2,501) p Value
Age, yrs 52.3  12.8 53.6  12.0 0.0027
Abbreviations
and Acronyms
BP = blood pressure
CBP = central blood
pressure
CI = conﬁdence interval
cuff BP = peripheral blood
pressure
DBP = diastolic blood
pressure
PP = pulse pressure
SBP = systolic blood
pressure
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1781by auscultation of the Korotkoff sounds or by automatic BP
monitors (cuff BP), and a cutoff of 140/90 mm Hg has been
used to diagnose high BP (3–5). With the recent evolution
of evidence-based practice, ambulatory BP, which provides
a better prognostic value, has been suggested as the reference
standard for the management of hypertension (6).
Nevertheless, both ambulatory BP and conventional cuff
BP are measured at brachial arteries, and BP ampliﬁcation
from the central aorta to peripheral arteries is well known
to vary substantially among individuals and to cause
conceivable discrepancies between central blood pressure
(CBP) and cuff BP readings (7–12). Currently, noninvasive
CBP can be obtained with either tonometry-based (9,13–15)
or cuff-based techniques (16–18). Growing evidence (19)
suggests that there are major discrepancies in CBP among
people with similar peripheral BP levels (20,21), central
BP may be more relevant than peripheral BP in predicting
target organ damage and cardiovascular outcomes (22–24),
central and peripheral BP may respond differently to anti-
hypertensive medication in randomized controlled trials
(25,26), and end-organ changes after antihypertensive
medication are more strongly related to CBP than peripheral
BP (27–29). We have previously suggested that CBP and
ambulatory BP may have similar abilities to predict future
outcomes (30). Because CBP as a reference standard may
further improve current hypertension management, it is
important for clinicians to utilize CBP values to classify
patients with respect to their hypertension. However,
threshold values of CBP have never been investigated in
longitudinal event-based studies.
We derived an operational threshold for CBP based
on an outcome-driven approach (31,32) and validated
this threshold in another, independent cohort to examine
its discriminatory ability for long-term cardiovascular
outcomes.Body mass index,
kg/m2
24.7  3.6 24.2  3.2 <0.0001
Total cholesterol,
mg/dl
198.1  37.5 192.3  39.1 <0.0001
LDL, mg/dl 123.1  34.3 122.0  37.3 0.3927
HDL, mg/dl 50.9  13.1 47.7  16.8 <0.0001
Heart rate,
beats/min
73.6  9.9 73.1  10.2 0.1620
Cuff SBP, mm Hg 139.2  23.6 122.4  17.0 <0.0001
Cuff DBP, mm Hg 88  14.6 68.2  10.2 <0.0001
Cuff PP, mm Hg 51.2  16.6 54.2  12.2 <0.0001
Central SBP, mm Hg 127.6  23.7 111.8  16.1 <0.0001
Central DBP, mm Hg 86.3  14.2 70.2  10.3 <0.0001
Central PP, mm Hg 41.3  15.7 41.5  11.0 0.6560
Male 53 45 <0.0001
Dyslipidemia 57 69 <0.0001
Smoking 24 24 0.517
Optimal BP 18 46 <0.0001
Prehypertension 30 38 <0.0001
Hypertension 52 16 <0.0001
Values are mean  SD or %.
BP ¼ blood pressure; DBP ¼ diastolic blood pressure; HDL ¼ high-density lipoprotein; LDL ¼ low-
density lipoprotein; MBP ¼ mean blood pressure; PP ¼ pulse pressure; SBP ¼ systolic blood
pressure.Methods
Study population. We performed the present analysis
using individuals from 2 independently and prospectively
recruited cohorts in Taiwan that were followed longitudi-
nally. We have previously reported the relationship between
CBP and cardiovascular mortality (23), and the participants
of that study served as a derivation cohort from which the
diagnostic thresholds were generated. Subsequently, the
discriminatory ability of these thresholds for cardiovascular
mortality was tested in a validation cohort. Details of the re-
cruitment process and study protocols for the derivation and
validation cohorts have been reported elsewhere (23,33–35)
and are summarized in Table 1. All participants gave
informed consent before enrollment.
Derivation cohort. The derivation cohort for generating
diagnostic thresholds included 1,272 normotensive and
untreated hypertensive (systolic blood pressure [SBP] 140
mm Hg or diastolic blood pressure [DBP] 90 mm Hg with-
out any previous antihypertensive medication) Taiwaneseparticipants (674men, age 30 to 79
years) from a previous community-
based survey conducted in 1992 to
1993 (36).
Validation cohort. Performance
of the derived thresholds was
determined in the validation
cohort from CVDFACTS (the
Cardiovascular Disease Risk
Factors Two-Township Study),
a community-based follow-up
study focusing on risk-factor
evaluation and cardiovascular
disease development in Taiwan
(34,35). Of the participants in CVDFACTS, a total of
3,386 individuals had undergone CBP measurements during
their cycle 4 examination (1997 to 1999). From that group,
we excluded 617 participants who were treated with anti-
hypertensive drugs, 268 subjects with cardiovascular diseases
or stroke history. Thus, data on the 2,501 individuals of the
validation cohort were utilized in the present analyses.
Follow-up. By linking our database with the National
Death Registry, we retrieved the dates and causes of death of
all participants in the derivation and validation cohorts.
Individuals that did not appear in the National Death
Registry on December 31, 2007, were considered to be
survivors. The median follow-up durations of the derivation
and validation cohorts were 15 and 10 years, respectively.
Table 2
CBP Levels and Cardiovascular Mortalities With Different Cuff SBP and DBP Cutoffs Based on Conventional Criteria
in the Derivation Cohort
Hypertension Staging Category
Diagnostic Thresholds for
Cuff BP, mm Hg Cardiovascular Mortalities, %
Corresponding CBP Levels, mm Hg
(95% CI)
Optimal–pre-hypertension SBP 120 2.7 112.80 (111.15–113.61)
DBP 80 4 80.92 (79.60–82.22)
Prehypertension–hypertension SBP 140 4.3 132.43 (130.89–133.88)
DBP 90 5 90.98 (89.93–91.96)
The cutoff criteria are based on international standards (3–5). Point estimates and 95% conﬁdence intervals (CIs) were obtained from the bootstrap distribution of 1,000 random samples with
replacement of CBP levels for participants in the derivation cohort.
CBP ¼ central blood pressure; other abbreviations as in Table 1.
Figure 1
The Sensitivity and Speciﬁcity of Cuff SBP and
Central SBP for Predicting Cardiovascular Mortality
in the Derivation Cohort
With increasing systolic blood pressure (SBP) cutoff values, speciﬁcity (SPE)
improved at the expense of decreasing sensitivity (SEN). Reasonable cutoff limits
for central SBP can then be determined by approximating based on the sensitivity
or speciﬁcity of the guideline-endorsed cuff SBP cutoff points as demonstrated in
Table 3. cuff BP ¼ peripheral blood pressure.
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1782BP measurement. Three or more sets of peripheral BP
measurements (cuff BP) were obtained from the right arm,
with 5 min between readings; measurements were made
only after each person was seated for 5 min. Cuff BP,
which was measured manually by experienced clinicians
using a mercury sphygmomanometer and standard-sized
cuffs, is reported as the average of the last 2 consecutive
measurements.
In the derivation cohort, right common carotid artery
pressure waveforms were calibrated with brachial mean
blood pressure and DBP to obtain the carotid BP (13).
The carotid artery pressure waveforms, registered non-
invasively with a tonometer (22,36), have been demon-
strated to closely resemble central aortic pressure waveforms
(13,37,38). In the validation cohort, CBP was obtained
with a SphygmoCor device (AtCor Medical, Sydney,
Australia) using radial arterial pressure waveforms and
a validated generalized transfer function, according to the
manufacturer’s instructions (39). Radial arterial pressure
waveforms, obtained by applanation tonometry using
a solid-state high-ﬁdelity external Millar transducer, were
calibrated with cuff SBP and DBP values, and then
mathematically transformed by the validated transfer func-
tion (39) into corresponding central aortic pressure wave-
forms. Cuff and central pulse pressures (PPs) were
calculated as: (SBP  DBP).
Other measurements. Early in the morning after an
overnight fast, serum and plasma samples were drawn for
glucose, lipids, and other biochemical measurements from
patients in a sitting position. Dyslipidemia was deﬁned
according to “The Third Report of the National Cholesterol
Education Program Expert Panel on Detection, Evaluation,
and Treatment of High Blood Cholesterol in Adults (Adult
Treatment Panel III)” (40). A classiﬁcation of diabetes
mellitus was indicated for participants with a fasting
glucose 126 mg/dl, or who were taking antidiabetic
medication (41). In both cohorts, individuals undergoing BP
measurements also completed a questionnaire-based inter-
view containing items on demography, lifestyle, self-
reported health conditions, medication history, and family
history of disease.
Statistical analysis. Data are presented as percent or mean
 SD. Student t test and chi-square test were used for
between-group comparisons when appropriate.We obtained diagnostic thresholds and their 95% conﬁ-
dence intervals (CIs) for CBP similar to a previous study
deriving cutoffs for ambulatory BP and conventionally
measured home BP (31,42). First, we identiﬁed the partic-
ipants in the derivation cohort with a cuff BP that coincided
with thresholds proposed by international guidelines (3–5)
and calculated the corresponding cardiovascular mortalities
(Table 2). Second, we used the bootstrap method for each
cutoff by randomly selecting CBP levels 1,000 times from
those of the corresponding identiﬁed participants. Third, we
obtained the mean and 2.5th and 97.5th percentiles from
the re-sampling distribution to serve as the diagnostic
thresholds of CBP with 95% CIs. Alternatively, we esti-
mated the sensitivity and speciﬁcity of cuff SBP cutoff limits
for predicting cardiovascular mortality (Fig. 1).
In addition, to conform with current guideline-endorsed
management of arterial hypertension (3–5) based on cuff
BP, we calculated the sensitivity and speciﬁcity of each
cutoff point of central and cuff SBP in 10-mm Hg
increments from 80 to 180 mm Hg for cardiovascular
mortality. Considering that the sensitivity of cuff BP was
Figure 2
Performance of the CBP Diagnostic Thresholds in the
Validation Cohort
Incorporating the dichotomous variable of deﬁned hypertension based on different
central blood pressure (CBP) Levels (x-axis) and the resulting contribution (Wald
Chi-square and model R2) to the predictive power of the Cox proportional hazards
model are shown. A CBP cutoff limit of 130/90 mm Hg was associated with
a higher Wald chi-square and model R2 than other thresholds.
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1783higher than its speciﬁcity in predicting cardiovascular
mortalities (Table 3), we then linked the points of central/
cuff SBP and sensitivity/speciﬁcity to ﬁnd the optimal
cutoff point for central SBP that had equal sensitivity and
approximate speciﬁcity (Fig. 1, Table 3). Furthermore, we
used the Wald chi-square analysis from the Cox propor-
tional hazard model to compare the discrimination among
varied cutoff points for central SBP for cardiovascular
mortality (Fig. 2).
A Cox proportional hazard model was constructed to
evaluate the performance of the proposed diagnostic
thresholds of CBP for predicting cardiovascular outcomes.
Survival time was calculated from the date of the CBP
measurement to the date of death or the end of follow-up
(December 31, 2011). The estimated hazard ratio of the
validation cohort was derived after accounting for sex, age,
body mass index, smoking, alcohol consumption, and serum
total cholesterol level. As with other large cohort studies (2),
BP was included ﬁrst as a continuous function in the Cox
regression model. Subsequently, on the basis of different
CBP thresholds for deﬁning hypertension, BP was incor-
porated into the model as a dichotomous variable to evaluate
the discriminative ability of the respective cutoff limits. The
discriminatory power of the differential models with and
without blood pressure was evaluated with prognostic
receiver-operating characteristic curves. The comparisons
between the areas under the curve of the prognostic receiver-
operating characteristic curves were made with a nonpara-
metric method developed by DeLong et al. (43). We further
used the integrated discrimination index, net reclassiﬁcation
index, and clinical net reclassiﬁcation index to evaluate the
reclassiﬁcation effects of central/cuff BP for predicting
future cardiovascular events (44). All statistics were calcu-
lated using SAS version 9.1 software (SAS Institute, Cary,
North Carolina).Results
Baseline characteristics of participants. In the derivation
and validation cohorts, data from a total of 1,272 (mean age,
52.3 years, 30 to 79 years) and 2,501 (mean age, 53.6 years,
32 to 90 years) participants, respectively, were used toTable 3
Determining Central SBP Cutoff Values Based on the
Sensitivity and Speciﬁcity Associated With Cuff SBP
Cutoff Values for Predicting Cardiovascular Mortality
Cutoff, mm Hg Sensitivity Speciﬁcity
Cuff SBP 120 0.906 0.237
Central SBP 110.49 0.906 0.292
Central SBP* 110 0.922 0.281
Cuff SBP 140 0.688 0.603
Central SBP 132.6 0.688 0.648
Central SBP* 130 0.741 0.600
See Figure 1 for the approximation process. *Cutoff values from the above central SBP values after
rounding.
Cuff SBP ¼ peripheral systolic blood pressure; SBP ¼ systolic blood pressure.evaluate diagnostic thresholds of CBP (Table 1). The mean
differences between cuff and central SBP in the derivation
and validation cohorts were 11.6  17.5 mm Hg and 10.7 
4.8 mmHg, and 9.9 14.2 mmHg and 12.7  5.0 mm Hg
between cuff and central PP, respectively (all p < 0.001).
Compared with the derivation cohort, participants in the
validation cohort were older, had lower cuff BP and CBP
values, and had a higher prevalence of dyslipidemia.
Derivation of diagnostic thresholds for CBP. Table 2
shows the risks of cardiovascular mortality in individuals
with cuff SBP/DBP values according to the cutoff limits
proposed by international guidelines. The risk was markedly
increased with increasing cuff SBP and DBP values. Using
a bootstrap procedure, we calculated the central SBP and
DBP values that correspond to these cuff BP limits
(Table 2).
Alternatively, as shown in Figure 1, the sensitivity and
speciﬁcity for predicting cardiovascular mortality with cuff
and central SBP were calculated. With the rise in SBP
cutoffs, the speciﬁcity improved but sensitivity dropped.
We then identiﬁed the respective sensitivity and speciﬁcity
of the cuff BP limits proposed by the guidelines. By
approximating the identiﬁed estimated sensitivity, we then
derived the central SBP levels corresponding to these limits
(Table 3).
On the basis of the analyses in Tables 2 and 3, we
proposed the outcome-driven diagnostic thresholds for CBP
after rounding the point estimates to an integer value ending
in 0 or 5 (Table 4). Based on these easy-to-remember
thresholds, categorization of BP distribution by CBP
could be achieved.
Table 4
Proposal for Outcome-Driven Diagnostic Thresholds
for CBP Measurement
Central SBP,
mm Hg
Central DBP,
mm Hg
Optimal BP <110 and <80
Pre-hypertension 110–129 and/or 80–89
Hypertension 130 and/or 90
Threshold values were obtained by rounding the point estimates reported in Tables 2 and 3 to an
integer value ending in 0 or 5.
Abbreviations as in Tables 1 and 2.
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by the proposed CBP thresholds in the validation
cohort. Cox proportional hazards modeling showed that
central SBP and central PP (per 10mmHg) were signiﬁcantly
associated with cardiovascular mortality (1.149, 95% CI:
1.032 to 1.279 and 1.102, 95% CI: 1.027 to 1.182), total
mortality (1.09, 95% CI: 1.031 to 1.152 and 1.065, 95% CI:
1.027 to 1.104), and stroke mortality (1.257, 95% CI: 1.07 to
1.476 and 1.117, 95% CI: 1.003 to 1.243) in the validation
cohort, respectively (all p < 0.01). By contrast, cuff SBP had
signiﬁcant association only with total mortality (1.061, 95%
CI: 1.004 to 1.122) and stroke mortality (1.204, 95% CI:
1.025 to 1.415), whereas cuff PP was only signiﬁcantly asso-
ciated with total mortality (1.042, 95% CI :1.003 to 1.082).
In addition, comparedwith cuff BP,CBPhad an additional
contribution to the prediction of future cardiovascular out-
comes across traditional cardiovascular risk factors dem-
onstrated by improved incremental C-index and integrated
discrimination index, and net reclassiﬁcation index for
cardiovascular and stroke mortality, respectively (Online
Table 1).
Table 5 shows the hazard ratio for cardiovascular out-
comes in different BP categories on the basis of the CBP
criteria proposed in Table 4. In the entire validation cohort,
the risk of developing cardiovascular outcomes was signiﬁ-
cantly higher in individuals with hypertension deﬁned as
a CBP value of 130/90 mm Hg than in those with optimal
BP. The performance of conventional international stan-
dards (3–5) and the CBP criteria in subgroup analysis in the
validation cohort is presented in the online supplementaryTable 5
Hazard Ratios for Total, Cardiovascular, and
Stroke Mortality in Relation to CBP at Entry in the
Validation Cohort (n ¼ 2,501)
Total
Death
Cardiovascular
Death
Stroke
Death
Endpoints 185 (7.4) 34 (1.36) 18 (0.72)
Pre-hypertension
vs. optimal BP
1.31 (0.87–3.35) 1.59 (0.57–4.43) 1.93 (0.45–8.31)
Hypertension vs.
optimal BP
2.14 (1.36–3.35) 3.08 (1.05–9.05) 6.12 (1.43–26.21)
Values are n (%) or hazard ratio (95% conﬁdence interval). Hazard ratios were adjusted for sex, age,
body mass index, smoking, and serum total cholesterol level. Staging was according to the criteria
for central blood pressure in Table 4.
Abbreviations as in Tables 1tables (all p for interaction with age and sex >0.05)
(Online Tables 2 to 4).
Performance of the CBP diagnostic thresholds in the
validation cohort. As shown in Figure 2, in a Cox
proportional hazards model, a CBP value of 130/90 mm Hg
was associated with a better discriminatory ability and
was characterized by higher Wald chi-square and model
R2 values than other diagnostic thresholds for deﬁning
hypertension.
Discussion
The present study is the ﬁrst, to our knowledge, to derive
and validate the outcome-driven diagnostic thresholds of
CBP for the diagnosis of hypertension. Building on a large
consensus, current guidelines rely on cuff BP measurements
made at a clinic or at home or on 24-h ambulatory BP
measurements to categorize individuals with different levels
of SBP and DBP; these categories are then used to predict
the future cardiovascular risks of these individuals (3,5,45).
However, all these criteria are based on noninvasive BP
measurements of brachial arterial pulses, which are gener-
ated from cardiac contractions and then transmitted from
the central aortic pulses, the origin of all arterial pulses.
Physiologically, with its close proximity to vital organs and
the better prognostic value (22–24,26,46), CBP should
be the most relevant BP relating to vascular events. Cuff
BP is not so much a surrogate, but a compromised measure
that is recorded because of technical limitations. With
accumulating evidence supporting the use of CBP for the
management of hypertension (3,26) and the available
techniques (9,13–18), deriving diagnostic thresholds of
CBP that conform to previous guidelines and that are
aligned with cuff BP is an important step. The other
strength of our study is that in addition to threshold deri-
vation through rigorous statistical methods, we also vali-
dated the discriminatory powers of the derived cutoff values
in another event-based cohort with long-term follow-up. In
the validation cohort, the CBP was measured with a tech-
nique (radial tonometry and the generalized transfer func-
tion of SphygmoCor) that is different from that used in the
derivation cohort (carotid tonometry). The consistent
results in the derivation and validation cohorts and the
comparable prognostic performances across different age
and sex subgroups (all p for interaction >0.05) (Online
Tables 3 and 4) suggest that our proposed thresholds
(Table 4) are both reliable and valid.
Although we rigorously derived and validated the diag-
nostic thresholds for CBP measurements for the diagnosis of
hypertension in agreement with current practice, caution
should still be exercised for the following reasons. The
relationship between BP and vascular mortality is contin-
uous throughout middle and older age, but individuals with
BP values that are lower than the threshold of current
guidelines for hypertension management are not guaranteed
to be free from cardiovascular risk (2). A recent systematic
JACC Vol. 62, No. 19, 2013 Cheng et al.
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1785review suggested that antihypertensive drugs that are used to
treat stage I hypertension have not been shown to reduce
mortality or morbidity in randomized controlled trials, and
this may again challenge the legitimacy of these guideline-
endorsed thresholds (47). These observations may not be
valid for ambulatory BP or for CBP, and more studies should
be conducted to clarify these issues. However, in our vali-
dation cohort, we did observe the best discriminatory power
for these particular CBP thresholds (i.e., 130/90 mm Hg)
for predicting cardiovascular mortality (Fig. 2).
Sharman et al. (48) demonstrated that wide variations in
the difference between cuff BP and CBP values can occur
among patients with a similar cuff BP. The magnitude of
variation is similar between healthy and diseased individuals,
which suggests that CBP measurements may further im-
prove risk stratiﬁcation. In this regard, although CBP and
cuff BP values are correlated closely with each other, it may
be inappropriate to directly assume from such a correlation
that cuff BP is a surrogate for CBP. Instead, by incorpo-
rating the CBP criteria into clinical practice, the possibility
of an incremental clinical beneﬁt in the management of
hypertension could be ascertained.
Age- and sex-speciﬁc reference values for CBP have been
provided in the Anglo-Cardiff Collaborative Trial (20). Both
cuff BP and CBP values increase with age, and a possible,
but not user-friendly, clinical application could be the use of
the reference values stratiﬁed by age and sex. However, in
current international guidelines, the classiﬁcation of cuff
BP values disregards age, sex, and other cardiovascular risk
factors. In our multivariate model, the results were consistent
after accounting for these factors. In line with current clinical
practice and considering the higher clinical events in the
aged population, we now propose diagnostic thresholds of
CBP without age and sex speciﬁcation.
Diagnostic reference values of CBP had been used to deﬁne
a special disease entity, spurious systolic hypertension, which
is characterized by high cuff BP and lowCBP (49). It has been
proposed to be a rather common phenomenon in young age
(50). Investigating a population of 750 individuals (352 men
and 398 women) age 26 to 31 years, Hulsen et al. (49) sug-
gested that participants with this condition have cardiovas-
cular risk proﬁles comparable to normotensive individuals.
They used the 90th percentile of central SBP distribution
to obtain the cutoffs of CBP (124/90 mm Hg for men and
120/90 mm Hg for women). The reference values were,
however, not representative of the general population and
were obtained solely for their research purposes.
The distribution of central SBP was studied in a health
check-up program in Japan in 10,756 participants (51).
Using the late systolic upstroke of the radial pressure wave
to represent central SBP with a HEM-9000AI monitor
(Omron Healthcare, Kyoto, Japan), they reported the
reference values of optimal and normal central SBP cate-
gories as 112.6  19.2 mm Hg and 129.2  14.9 mm Hg,
respectively, similar to our results. That study probably
represents the ﬁrst effort to report the diagnostic thresholdof CBP, but it was limited based on its study design, which
consisted of a cross-sectional population rather than an
event-based cohort. Therefore, the prognostic value of their
proposed diagnostic thresholds could not be further
evaluated.
Study limitations. Because our study population consisted
of 2 Taiwanese populations, the generalizability of our
study conclusions in terms of ethnicity is unclear. None-
theless, our thresholds are consistent with the similar
reference values proposed in the aforementioned Japanese
population (51).
The techniques used to measure CBP in the derivation
and validation cohorts were carotid tonometry and gener-
alized transfer function with a SphygmoCor monitor,
respectively, which are currently the 2 most popular CBP
measurement methods (52). Whether the same reference
values should be used for different methodologies is not
clear. Problems have been encountered during the derivation
process of diagnostic thresholds based on ambulatory BP
and traditional home BP measurements (31,53). However,
with similar results obtained with various techniques,
adoption of universal criteria for CBP for the diagnosis and
management of hypertension may become reasonable.
Neither cuff BP nor noninvasive CBP estimates are error
free when compared with invasively measured counterparts
(54). The relationship between BP and cardiovascular
outcomes could be affected by measurement errors, which
have been termed regression dilution bias or attenuation bias
(55,56). Although the effect of the measurement error on
the dilution of the prognostic value has been clearly delin-
eated, correction may be neither necessary nor appropriate in
most applications (57). In addition, the inﬂuence of
measurement errors on the discriminatory power of diag-
nostic cutoff values remains an unresolved issue for both
conventional cuff BP and CBP. These issues require further
research for clariﬁcation.Conclusions
We derived and validated the diagnostic thresholds of CBP
based on 2 independent event-based cohorts with long-term
follow-up. Consistent with the staging criteria of current
international guidelines for the diagnosis of hypertension,
we propose a CBP of 130/90 mm Hg to be used as cutoff
limits for normality because these values were characterized
by greater discriminatory power for cardiovascular mortality
in our validation cohort. The present report represents an
important step toward the application of the CBP concept to
clinical risk factor proﬁles for CVD.
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